Efficacy and Safety of Shea Nut Oil in Hemophilic Arthropathy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 114
- Hemophilia care and research center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age 20 years and above
- hemophilia A or B patients who reported painful (VAS ≥ 3) hemophilic arthropathy in ankles, elbows or knees for at least 6 months.
Exclusion Criteria:
- presence of joint infections
- any surgery on the joint in preceding 6 months
- intra-articular HA injection within the past 6 months
- history of rheumatoid arthritis,
- gouty arthropathy
- presence of neoplasm,
- allergy to shea nut oil production
- use of corticosteroids within 3 weeks prior to baseline and throughout the study
- use of anti-inflammatory agents 3 weeks prior to baseline and for the duration of the study,
- history of trauma associated with the signal joint,
- liver function tests greater than twice the upper limit of normal at baseline
- history of alcohol or substance abuse.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Shea nut oil
100% shea nut oil extract with 75% triterpene esters.
Daily dosage is three 750 mg soft gel capsules (2250 mg/per day) taken in the morning for 3 months
|
|
|
Placebo Comparator: Placebo
placebo which comprised 100% canola oil or starch mixed soybean oil
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain (visual analogue scale) and Change from Baseline Pain at 1 &3 months
Time Frame: baseline, 1 month, 3 months
|
The pain intensity will be evaluated subjectively on a visual analogue scale (0-100mm).
|
baseline, 1 month, 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CTX-II (ng/mmol creatinine) and Change from Baseline at 1 & 3 months
Time Frame: baseline, 1 month, 3 months
|
C-telopeptide fragments of type II collagen (CTX-II) in urine is a measure of type II collagen degradation and a biological marker of arthropathy.
|
baseline, 1 month, 3 months
|
|
Tumor Necrosis Factor alpha (pg/mL) and Change from Baseline at 1 & 3 months
Time Frame: baseline, 1 month, 3 months
|
TNF-alpha are one of inflammatory mediators that increase following hemarthrosis in hemophilic mice.
Plasma samples will tested by ELISA.
|
baseline, 1 month, 3 months
|
|
Ultrasonographic synovial thickness (mm) and Change from Baseline at 1 &3 months
Time Frame: baseline, 1 month, 3 months
|
Synovial thickness (mm) by ultrasonography were evaluated from the lateral, middle, and medial aspects of the anterior suprapatellar recess
|
baseline, 1 month, 3 months
|
|
Synovial hyperemia (score) and Change from Baseline at 1& 3 months
Time Frame: baseline, 1 month, 3 months
|
Power Doppler assessment of selected synovial sites is carried out with settings standardized to a pulse repetition frequency of 700 Hz.
The intensity of the blood flow in the synovium is scored into 0 to 3 (0=No flag; 1 = 1 flag; 2 = 2-3 flags; 3=>3 flags) adapted from Klukowska and Melchiorre et al
|
baseline, 1 month, 3 months
|
|
Short Form -36 score and Change from Baseline at 1 & 3 months
Time Frame: baseline, 1 month, 3 months
|
The SF-36 is filled out taking into account the person's condition in the last one month and scores range from 0 to 100, with higher scores indicating better health-related quality of life.
|
baseline, 1 month, 3 months
|
|
Hemophilia Joint Health Score (HJHS) and Change from Baseline at 1 & 3 months
Time Frame: baseline, 1 month, 3 months
|
The HJHS is a structured physical examination score evaluating the joint health in hemophilia patient.
The score for each joint is the sum of the individual items including swelling, swelling duration, muscle atrophy, axial alignment, crepitus of motion, flexion loss & extension loss, joint pain and strength.
A score of 20 suggests the worst possible damage/impairment in the evaluating joint.
|
baseline, 1 month, 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Tsung-Ying Li, Hemophilia care and research center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1-104-05-041
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilia
-
NCT04024176CompletedArthropathy | Moderate Hemophilia
-
NCT06568302TerminatedHemophilia B | Hemophilia a | Hemophilia a with Inhibitor | Hemophilia B with Inhibitor
-
NCT04072237CompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without Inhibitor
-
NCT03481946Completed
-
NCT02448680CompletedA Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (PERSEPT2)Hemophilia A With Inhibitors | Hemophilia B With Inhibitors
-
NCT03034044CompletedFactor VIII Deficiency, Congenital | Hemophilia A, Congenital | Factor 8 Deficiency, Congenital | Autosomal Hemophilia A | Classic Hemophilia
-
NCT04817462RecruitingHemophilia A, Severe | Hemophilia B, Severe
-
NCT02796222CompletedHemophilia A, Congenital | Hemophilia B, Congenital
-
NCT03407651CompletedHemophilia A With Inhibitor | Hemophilia B With Inhibitor
Clinical Trials on Placebo
-
NCT03827590UnknownAcute Bronchitis | Acute Upper Respiratory Tract Infection
-
NCT02177513Completed
-
NCT02935712CompletedMale Subjects With Type II Diabetes (T2DM)
-
NCT06767540Not yet recruiting
-
NCT03198624CompletedPharmacokinetics | Safety Issues
-
NCT02982187CompletedPulmonary Disease, Chronic Obstructive
-
NCT04693039Completed
-
NCT01610388Completed
-
NCT04388215UnknownHypertension | Dyslipidemias